Skip to main content
Erschienen in: Medical Oncology 1/2013

01.03.2013 | Original Paper

FISH analysis for TET2 deletion in a cohort of 362 Brazilian myeloid malignancies: correlation with karyotype abnormalities

verfasst von: Fábio Morato de Oliveira, Carlos Eduardo Miguel, Antônio Roberto Lucena-Araujo, Ana Silvia Gouvêa de Lima, Roberto Passetto Falcão, Eduardo Magalhães Rego

Erschienen in: Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

We investigated the prevalence of TET2 deletion by using a new FISH probe in a cohort of 362 Brazilian patients with myeloid neoplasms and their association with cytogenetic information (G-banding analysis). Normal karyotype was observed in 45.8 % of MDS (n = 44), 43.8 % of AML (n = 39) and 46.3 % of MPN (n = 82). Abnormalities of 4q24 (deletions, translocations or inversions) were associated with another chromosomal abnormality in four patients by G-banding analysis (2 MDS, 1 AML and 1 MPN). Interphase FISH analysis revealed deletion of TET2 in 21 patients (6 patients with abnormal karyotype and in 15 patients with normal karyotype). arrayCGH analysis revealed a cryptic deletion of the region 4q24 in all eight patients selected with myeloid malignancies (3 MDS, 1 AML and 4 MPN). Considering the significantly high cost of determining the mutational status of TET2 in patient samples by using conventional sequencing methods and sometimes the lack of regular use of SNP/aCGH array methodologies, FISH for the detection of TET2 abnormalities may become a potentially useful clinical tool. The search for alterations in TET2 gene may be important for the prediction of prognosis in normal/altered AML patients’ karyotype or in the disease evolution of patients with MNP and MDS.
Literatur
1.
Zurück zum Zitat Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009;114(1):144–7.PubMedCrossRef Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009;114(1):144–7.PubMedCrossRef
2.
Zurück zum Zitat Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289–301.PubMedCrossRef Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289–301.PubMedCrossRef
3.
Zurück zum Zitat Moran-Crusio K, Reavie L, Shih A, et al. TET2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20(1):11–24.PubMedCrossRef Moran-Crusio K, Reavie L, Shih A, et al. TET2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20(1):11–24.PubMedCrossRef
4.
Zurück zum Zitat Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010;70(2):447–52.PubMedCrossRef Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res. 2010;70(2):447–52.PubMedCrossRef
5.
Zurück zum Zitat Quivoron C, Couronné L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20(1):25–38.PubMedCrossRef Quivoron C, Couronné L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20(1):25–38.PubMedCrossRef
6.
Zurück zum Zitat La Starza R, Crescenzi B, Nofrini V, et al. FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions. Leuk Res. 2012;36(1):37–41.PubMedCrossRef La Starza R, Crescenzi B, Nofrini V, et al. FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions. Leuk Res. 2012;36(1):37–41.PubMedCrossRef
7.
Zurück zum Zitat Pronier E, Delhommeau F. Role of TET2 mutations in myeloproliferative neoplasms. Curr Hematol Malig Rep. 2012;7(1):57–64.PubMedCrossRef Pronier E, Delhommeau F. Role of TET2 mutations in myeloproliferative neoplasms. Curr Hematol Malig Rep. 2012;7(1):57–64.PubMedCrossRef
8.
Zurück zum Zitat Tripodi J, Hoffman R, Najfeld V, Weinberg R. Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms. Cancer Manag Res. 2010;2:219–23.PubMed Tripodi J, Hoffman R, Najfeld V, Weinberg R. Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms. Cancer Manag Res. 2010;2:219–23.PubMed
9.
Zurück zum Zitat Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a cancer and leukemia group b study. J Clin Oncol. 2011;29(10):1373–81.PubMedCrossRef Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a cancer and leukemia group b study. J Clin Oncol. 2011;29(10):1373–81.PubMedCrossRef
10.
Zurück zum Zitat Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011;117(21):198–206.CrossRef Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011;117(21):198–206.CrossRef
11.
Zurück zum Zitat Roche-Lestienne C, Marceau A, Labis E, et al. Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia. Leukemia. 2011;25(10):1661–4.PubMedCrossRef Roche-Lestienne C, Marceau A, Labis E, et al. Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia. Leukemia. 2011;25(10):1661–4.PubMedCrossRef
12.
Zurück zum Zitat Pignataro DS, Abdel-Wahab O. FISHing for TET2: utility of FISH for TET2 deletions detection in clinical samples. Leuk Res. 2012;36(1):25–6.PubMedCrossRef Pignataro DS, Abdel-Wahab O. FISHing for TET2: utility of FISH for TET2 deletions detection in clinical samples. Leuk Res. 2012;36(1):25–6.PubMedCrossRef
13.
Zurück zum Zitat Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292–302.PubMedCrossRef Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292–302.PubMedCrossRef
14.
Zurück zum Zitat Morato de Oliveira F, Lucena-Araujo AR, Favarin MD, et al. Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodisplastic syndrome: correlation with G-banding analysis and FISH. Exp Hematol. 2012. doi:10.1016/j.exphem.2012.10.009 (Epub ahead of print). Morato de Oliveira F, Lucena-Araujo AR, Favarin MD, et al. Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodisplastic syndrome: correlation with G-banding analysis and FISH. Exp Hematol. 2012. doi:10.​1016/​j.​exphem.​2012.​10.​009 (Epub ahead of print).
15.
Zurück zum Zitat Shaffer LG, Slovak ML, Campbell LJ, editors. ISCN 2009: an international system for human cytogenetic nomenclature 2009. Basel: S. Karger; 2009. Shaffer LG, Slovak ML, Campbell LJ, editors. ISCN 2009: an international system for human cytogenetic nomenclature 2009. Basel: S. Karger; 2009.
16.
Zurück zum Zitat Starczynowski DT, Vercauteren S, Telenius A, et al. High-resolution whole genome tiling path array CGH analysis of CD34 + cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood. 2008;112(8):3412–24.PubMedCrossRef Starczynowski DT, Vercauteren S, Telenius A, et al. High-resolution whole genome tiling path array CGH analysis of CD34 + cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood. 2008;112(8):3412–24.PubMedCrossRef
17.
Zurück zum Zitat Bacher U, Weissmann S, Kohlmann A, et al. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele. Br J Haematol. 2012;156(1):67–75.PubMedCrossRef Bacher U, Weissmann S, Kohlmann A, et al. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele. Br J Haematol. 2012;156(1):67–75.PubMedCrossRef
18.
Zurück zum Zitat Kohlmann A, Grossmann V, Klein HU, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28(24):3858–65.PubMedCrossRef Kohlmann A, Grossmann V, Klein HU, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28(24):3858–65.PubMedCrossRef
19.
Zurück zum Zitat Schaub FX, Looser R, Li S, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010;115(10):2003–7.PubMedCrossRef Schaub FX, Looser R, Li S, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010;115(10):2003–7.PubMedCrossRef
20.
Zurück zum Zitat Saint-Martin C, Leroy G, Delhommeau F, et al. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood. 2009;114(8):1628–32.PubMedCrossRef Saint-Martin C, Leroy G, Delhommeau F, et al. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood. 2009;114(8):1628–32.PubMedCrossRef
21.
Zurück zum Zitat Kosmider O, Gelsi-Boyer V, Ciudad M, et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009;94(12):1676–81.PubMedCrossRef Kosmider O, Gelsi-Boyer V, Ciudad M, et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009;94(12):1676–81.PubMedCrossRef
22.
Zurück zum Zitat Kosmider O, Gelsi-Boyer V, Cheok M, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood. 2009;114(15):3285–91.PubMedCrossRef Kosmider O, Gelsi-Boyer V, Cheok M, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood. 2009;114(15):3285–91.PubMedCrossRef
23.
Zurück zum Zitat Nibourel O, Kosmider O, Cheok M, et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood. 2010;116(7):1132–5.PubMedCrossRef Nibourel O, Kosmider O, Cheok M, et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood. 2010;116(7):1132–5.PubMedCrossRef
24.
Zurück zum Zitat Brecqueville M, Rey J, Bertucci F, et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosom Cancer. 2012;51:743–55.PubMedCrossRef Brecqueville M, Rey J, Bertucci F, et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosom Cancer. 2012;51:743–55.PubMedCrossRef
25.
Zurück zum Zitat Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS MDS/MPN and AML. Leukemia. 2009;23(7):1343–5.PubMedCrossRef Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS MDS/MPN and AML. Leukemia. 2009;23(7):1343–5.PubMedCrossRef
26.
Zurück zum Zitat Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009;23(5):905–11.PubMedCrossRef Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009;23(5):905–11.PubMedCrossRef
27.
Zurück zum Zitat Zamora L, Xandri M, Garcia O, et al. Association of JAK2 mutation status and cytogenetic abnormalities at diagnosis in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. Am J Clin Pathol. 2012;137(4):677–8.PubMedCrossRef Zamora L, Xandri M, Garcia O, et al. Association of JAK2 mutation status and cytogenetic abnormalities at diagnosis in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. Am J Clin Pathol. 2012;137(4):677–8.PubMedCrossRef
28.
Zurück zum Zitat Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol. 2011;29(5):504–15.PubMedCrossRef Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol. 2011;29(5):504–15.PubMedCrossRef
29.
Zurück zum Zitat Falini B, Martelli MP. NPM1-mutated AML: targeting by disassembling. Blood. 2011;118(11):2936–8.PubMedCrossRef Falini B, Martelli MP. NPM1-mutated AML: targeting by disassembling. Blood. 2011;118(11):2936–8.PubMedCrossRef
Metadaten
Titel
FISH analysis for TET2 deletion in a cohort of 362 Brazilian myeloid malignancies: correlation with karyotype abnormalities
verfasst von
Fábio Morato de Oliveira
Carlos Eduardo Miguel
Antônio Roberto Lucena-Araujo
Ana Silvia Gouvêa de Lima
Roberto Passetto Falcão
Eduardo Magalhães Rego
Publikationsdatum
01.03.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 1/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0483-1

Weitere Artikel der Ausgabe 1/2013

Medical Oncology 1/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.